---

Not Medical Advice: This article is an educational review of scientific literature and does not account for individual health conditions. Always consult with healthcare professionals before making any health-related decisions.

I recently saw a headline from Everyday Health asking, "Is It Safe to Take B6, B12 and Folate With Blood Pressure Medication?" This immediately caught my eye. It's a great question because B-vitamin supplements are incredibly popular, often marketed for energy, brain health, and, yes, heart health.

As someone who spends a lot of time reading clinical papers, this got me wondering what the high-quality evidence actually says about this combination for cardiovascular disease. The theory makes perfect sense, but does it hold up in real-world clinical trials? I decided to dig into the data to find out.

The Homocysteine Theory: Why B-Vitamins Became a Focus

For years, scientists have known about a substance in our blood called homocysteine. Think of it as a type of amino acid. Multiple studies have shown that high levels of homocysteine are a risk factor for cardiovascular disease, potentially contributing to things like endothelial dysfunction (damage to the lining of blood vessels) and inflammation ^[3].

Here’s where B-vitamins come in. Your body uses folic acid (vitamin B9), vitamin B6, and vitamin B12 as essential tools to break down homocysteine and convert it into harmless substances. 

So, the logic was simple: 

1. High homocysteine is bad for the heart ^[3]. 

2. Studies have shown that B-vitamins can lower homocysteine ^[4]. 

3. Therefore, the hypothesis was that taking B-vitamins would protect the heart.

It’s a clean, compelling story. But when researchers tested it in large-scale trials, the results were not what everyone expected.

What Does the Research Actually Show?

When we look past the theory and into the clinical trial data, a more complicated picture emerges. The supplements did exactly what they were supposed to do on paper, but the ultimate outcome was surprising.

Some Promising Signs (But Not the Whole Story)

It's not that B-vitamins do nothing. In fact, studies have identified some clear, measurable benefits.

For instance, one meta-analysis reported that folic acid supplementation led to a significant reduction in carotid intima-media thickness ^[1]. In simple terms, this is a measurement of the thickness of the artery walls in your neck. Thicker walls can be a sign of atherosclerosis (plaque buildup), so reducing this thickness is a positive sign.

Another meta-analysis in patients with coronary heart disease found that a combination of folic acid, B6, and B12 was associated with lower homocysteine levels and a reduced incidence of vascular restenosis ^[4] — that's the re-narrowing of a blood vessel after a procedure like stenting.

So, the supplements were working on these specific markers. But this leads to the most important question.

The Big Question: Do They Actually Prevent Heart Attacks?

This is where the compelling theory falls apart.

The same meta-analysis that showed a benefit for restenosis looked at the ultimate outcomes: major cardiovascular events (like heart attacks and strokes) and death. The conclusion was clear: combined B-vitamin supplementation did not significantly reduce the incidence of major cardiovascular events or cardiovascular-related mortality in patients with coronary heart disease ^[4].

In other words, while studies indicated the vitamins lowered homocysteine and were associated with some structural improvements in the arteries, it just didn't translate to saving lives or preventing the major events people are trying to avoid.

Another review found that B-vitamin supplementation seemed to offer the most benefit in people with normal kidney function and those without very recent or unstable heart conditions ^[1]. This suggests that it's not a one-size-fits-all solution and may not be appropriate for everyone, especially those who are already at very high risk.

A Surprising Warning: When More is Worse

The most cautionary piece of evidence comes from a study looking at rheumatoid arthritis patients taking methotrexate, a common medication for the condition. Since methotrexate can deplete folate, patients are routinely prescribed folic acid.

Researchers compared the outcomes for patients taking high doses of folic acid versus low doses. The results were startling: patients on high-dose folic acid had a significantly higher risk of major adverse cardiovascular events ^[2]. This is a critical reminder that even with something as seemingly harmless as a vitamin, the dose and the patient context matter immensely. "Natural" doesn't always mean safe, and more is definitely not always better.

So What's the Bottom Line?

Looking at the full body of evidence, the story of B-vitamins and heart disease is a classic example of a promising lab theory that didn't fully pan out in large-scale human trials.

* What the research is fairly confident about: B-vitamin combinations (folic acid, B6, B12) are very effective at lowering homocysteine levels ^[4]. They can also positively affect some secondary markers, like artery wall thickness ^[1].

* Where it gets murky: The crucial link between lowering homocysteine with B-vitamins and actually preventing heart attacks or strokes is weak to non-existent in most broad populations studied so far ^[4]. The benefit just isn't there for general prevention.

* The key thing most people miss: There's a potential for harm, especially with high doses in specific patient groups ^[2]. The assumption that B-vitamins are universally beneficial for the heart is not supported by the current evidence and may even be counterproductive in some cases.

---

References

[1] Miao Y, Guo Y, Chen Y, et al. The effect of B-vitamins on the prevention and treatment of cardiovascular diseases: a systematic review and meta-analysis. Nutrition reviews. 2024. PMID: 37850302
https://pubmed.ncbi.nlm.nih.gov/37850302/

[2] Meng H, So H, Yan X, et al. High-dose folic acid supplement is associated with increased cardiovascular risk in rheumatoid arthritis patients on methotrexate. Therapeutic advances in musculoskeletal disease. 2026. PMID: 41768520
https://pubmed.ncbi.nlm.nih.gov/41768520/

[3] D'Elia S, Morello M, Titolo G, et al. Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. Journal of cardiovascular development and disease. 2025. PMID: 41149254
https://pubmed.ncbi.nlm.nih.gov/41149254/

[4] Guo L, Shi X, Wang G, et al. Combined B-vitamin supplementation on homocysteine and vascular outcomes in coronary heart disease: a meta-analysis. Annals of medicine. 2026. PMID: 41615824
https://pubmed.ncbi.nlm.nih.gov/41615824/